CoChat

Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors

Open access
Polonsky, William, Henry, Robert · 2016 · Patient Preference and Adherence

The DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index; none of the 86 sources its claims cite is checked for support yet.

Abstract

At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence.

Overview

CoChat Summary

## TL;DR

This review argues that poor medication adherence in type 2 diabetes is common, often affecting at least half of patients, and is tied to worse glycemic control, higher costs, and higher mortality. It highlights two broad modifiable drivers: treatment burden and patients’ treatment-related beliefs.

## Key findings

  • Reported poor medication adherence in T2D ranged from 38% to 93% across studies, largely because definitions and methods varied; using MPR ≥80%, adherence was 47.3% for dipeptidyl peptidase-4 inhibitors, 41.2% for sulfonylureas, and 36.7% for thiazolidinediones in a 238,000-patient MarketScan analysis.
  • Poor adherence was associated with worse outcomes: among >11,000 veterans, MPR <80% was significantly associated with poor glycemic control (HbA1c >8%, P<0.001); in 1,198 survey respondents, each 1-point drop in self-reported adherence was linked to a 0.21% increase in HbA1c and increases of 4.6%, 20.4%, and 20.9% in physician, ER, and hospital visits.
  • Mortality was higher with poor adherence: in 15,984 UK patients, poor adherence and missed visits were each associated with a 1.6-fold increase in all-cause mortality (P<0.001); another study reported an odds ratio of 1.8 (P<0.001).
  • Economic impact was substantial: improved adherence was projected to reduce hospitalization/ER risk by 13%, worsening adherence to raise it by 15%, and one analysis estimated annual savings of $4.7 billion with improved adherence and $3.6 billion with reduced poor adherence.

## Methods

  • Narrative review of the literature on medication adherence in T2D, focusing on the scope of the problem, consequences, key contributors, interventions, and future developments.
  • The paper synthesizes findings from retrospective/observational claim-database studies, surveys, and meta-analyses; it cites examples including analyses of 238,000 MarketScan patients, >11,000 veterans, 1,198 survey respondents, and other large database studies.
  • Main analysis is qualitative synthesis of reported adherence rates, outcomes, and modifiable contributors, with attention to common adherence metrics such as medication possession ratio (MPR) ≥80% and persistence definitions.

## Limitations

  • The paper states that much of the evidence comes from retrospective or observational claim-database studies using widely varying definitions, making findings difficult to interpret.
  • It states that intervention evidence is limited because adherence measures vary widely, hard outcomes are often lacking, interventions are not clearly explained, and follow-up is often inadequate.
  • Evident from the text: this is a review, not a new primary study, so its conclusions depend on the quality and comparability of the cited literature.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/ppa.s106821

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Prevalence of diagnosed diabetes among adults ≥20 years old from the NHANES of 1988–1994 and 1999–2010. Note: Data from a previous study.4 Abbreviations: NHANES, National Health and Nutrition Examination Survey; BMI, body mass index.
Figure 1 Prevalence of diagnosed diabetes among adults ≥20 years old from the NHANES of 1988–1994 and 1999–2010. Note: Data from a previous study.4 Abbreviations: NHANES, National Health and Nutrition Examination Survey; BMI, body mass index.CC BY-NC · PubMed Central
Figure 2 Percentage of patients discontinuing therapy (>60 days without drug) with oral hypoglycemic drugs during a 1-year follow-up of patients initiating therapy. Note: Data from a previous study.18 Abbreviation: TZD, thiazolidinedione.
Figure 2 Percentage of patients discontinuing therapy (>60 days without drug) with oral hypoglycemic drugs during a 1-year follow-up of patients initiating therapy. Note: Data from a previous study.18 Abbreviation: TZD, thiazolidinedione.CC BY-NC · PubMed Central
Figure 3 Percentage of patients with low, medium, or high adherence to antidiabetic medication based on the MMAS score according to the occurrence of recent hypoglycemic episodes. Notes: *P<0.05 vs never hypoglycemia. Data from a previous study.37 Abbreviation: MMAS, Morisky Medication Adherence Scale.
Figure 3 Percentage of patients with low, medium, or high adherence to antidiabetic medication based on the MMAS score according to the occurrence of recent hypoglycemic episodes. Notes: *P<0.05 vs never hypoglycemia. Data from a previous study.37 Abbreviation: MMAS, Morisky Medication Adherence Scale.CC BY-NC · PubMed Central

Verification

Claims the paper makes

0 Valid · 1 Not valid · 57 Not checked · 17 Own results and interpretations

49 more claims

Create a free account to see all 75 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 20
  • Probably not a substantial claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 74 references

Cited by

Items 601–700 of 761

Metadata

Authors
Polonsky, W., & Henry, R.
Affiliations
University of California San Diego (US)
Corresponding author
Polonsky, William
Venue
Patient Preference and Adherence
Published
2016-07
Volume
Volume 10
Pages
1299-1307
ISSN
1177-889X (ISSN-L)
OpenAlex
W2493860075
Cited by
784
References
77
Citations by year
2026: 93 · 2025: 97 · 2024: 89 · 2023: 82 · 2022: 108 · 2021: 106 · 2020: 106 · 2019: 54 · 2018: 34 · 2017: 13 · 2016: 2
FWCI
5.93
Type
journal article
Language
en
Open access
Locations
  • Patient Preference and Adherence (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
Intarcia Therapeutics
Topics
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
medication adherence, type 2 diabetes, glycemic control, barriers to adherence, medication beliefs, medication burden, out-of-pocket costs, hypoglycemia, treatment complexity, clinical inertia, socioeconomic factors, diabetes complications, drug delivery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.